BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO

BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO

Bibliographic Details
Main Authors:	Hammitzsch, A, de Wit, J, Ridley, A, Al-Mossawi, M, Knapp, S, Bowness, P
Format:	Journal article
Published:	2014

Similar Items

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
by: Hammitzsch, A, et al.
Published: (2015)

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
by: Hammitzsch, A, et al.
Published: (2018)

Elevated type-17 cytokines are present in Axial Spondyloarthritis stool
by: Brough, I, et al.
Published: (2024)

SUPPRESSION OF IN-VITRO TYPE-17 RESPONSES IN SPA PATIENTS USING SMALL MOLECULE ROR-gamma T INHIBITORS
by: De Wit, J, et al.
Published: (2014)

The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis
by: Al-Mossawi, M, et al.
Published: (2013)

The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis.
by: Al-Mossawi, M, et al.
Published: (2013)

miR-10b-5p is a novel Th17 regulator present in Th17 cells from Ankylosing Spondylitis
by: Chen, L, et al.
Published: (2017)

Novel therapeutic targets in axial spondyloarthritis
by: Worth, C, et al.
Published: (2018)

Pathogenic immune responses in Spondyloarthritis
by: Al-Mossawi, M
Published: (2016)

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis.
by: Chen, L, et al.
Published: (2015)

CHARACTERIZING TYPE 17 IMMUNE RESPONSES IN ANKYLOSING SPONDYLITIS
by: Al-Mossawi, H, et al.
Published: (2013)

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates
by: Simone, D, et al.
Published: (2021)

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates
by: Simone, D, et al.
Published: (2021)

T cell phenotype and function in Spondyloarthritis
by: Ridley, AL
Published: (2013)

Unique trancriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis
by: Al-Mossawi, M, et al.
Published: (2017)

HLA-B27 and KIR3DL2 Interactions Promote The Differentiation and Survival Of Proinflammatory T Cells In Spondyloarthritis
by: Ridley, A, et al.
Published: (2013)

Discovery of BET bromodomain inhibitors and their role in target validation
by: Mueller, S, et al.
Published: (2014)

RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.
by: de Wit, J, et al.
Published: (2015)

Small-molecule bromodomain inhibitors for cancer therapy
by: Qi, J, et al.
Published: (2010)

Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
by: Ferguson, F, et al.
Published: (2013)

The role of HLA-B27 in spondyloarthritis.
by: Allen, R, et al.
Published: (1999)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
by: Ciceri, P, et al.
Published: (2014)

The KIRs of HLA-B27: the role of HLA-B27 KIR interactions in infection and spondyloarthritis
by: Wong-Baeza, I, et al.
Published: (2011)

Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
by: Popp, T, et al.
Published: (2016)

Developing small molecule inhibitors of the CREBBP bromodomain-histone interaction
by: Rooney, T, et al.
Published: (2012)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
by: Philpott, M, et al.
Published: (2011)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
by: Philpott, M, et al.
Published: (2011)

Developing inhibitors of bromodomain-histone interactions
by: Hewings, D
Published: (2014)

Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA-B27 licenses pathogenic T cell differentiation in spondyloarthritis
by: Ridley, A, et al.
Published: (2016)

Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
by: Ahmed, S, et al.
Published: (2024)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
by: Lori, L, et al.
Published: (2016)

The bromodomain interaction module.
by: Filippakopoulos, P, et al.
Published: (2012)

The bromodomain interaction module
by: Filippakopoulos, P, et al.
Published: (2012)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
by: Ciceri, P, et al.
Published: (2014)

Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.
by: Catherine, S, et al.
Published: (2005)

Bromodomains as therapeutic targets.
by: Muller, S, et al.
Published: (2011)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
by: Filippakopoulos, P, et al.
Published: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
by: Filippakopoulos, P, et al.
Published: (2012)

THE ROLE OF HLA-B27 KIR3DL2 INTERACTIONS IN THE PATHOGENESIS OF SPONDYLOARTHRITIS
by: Kollnberger, S, et al.
Published: (2012)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
by: Hay, D, et al.
Published: (2013)